1. Home
  2. KZIA vs KAVL Comparison

KZIA vs KAVL Comparison

Compare KZIA & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • KAVL
  • Stock Information
  • Founded
  • KZIA 1994
  • KAVL 1998
  • Country
  • KZIA Australia
  • KAVL United States
  • Employees
  • KZIA N/A
  • KAVL N/A
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • KAVL Medicinal Chemicals and Botanical Products
  • Sector
  • KZIA Health Care
  • KAVL Health Care
  • Exchange
  • KZIA Nasdaq
  • KAVL Nasdaq
  • Market Cap
  • KZIA 7.8M
  • KAVL 11.0M
  • IPO Year
  • KZIA 1999
  • KAVL N/A
  • Fundamental
  • Price
  • KZIA $1.08
  • KAVL $1.45
  • Analyst Decision
  • KZIA Strong Buy
  • KAVL
  • Analyst Count
  • KZIA 2
  • KAVL 0
  • Target Price
  • KZIA $11.50
  • KAVL N/A
  • AVG Volume (30 Days)
  • KZIA 5.5M
  • KAVL 523.7K
  • Earning Date
  • KZIA 03-26-2025
  • KAVL 03-24-2025
  • Dividend Yield
  • KZIA N/A
  • KAVL N/A
  • EPS Growth
  • KZIA N/A
  • KAVL N/A
  • EPS
  • KZIA N/A
  • KAVL N/A
  • Revenue
  • KZIA $1,655,324.00
  • KAVL $10,108,906.00
  • Revenue This Year
  • KZIA $806.89
  • KAVL $652.90
  • Revenue Next Year
  • KZIA N/A
  • KAVL N/A
  • P/E Ratio
  • KZIA N/A
  • KAVL N/A
  • Revenue Growth
  • KZIA 248000.00
  • KAVL N/A
  • 52 Week Low
  • KZIA $1.15
  • KAVL $0.58
  • 52 Week High
  • KZIA $15.80
  • KAVL $9.69
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 32.04
  • KAVL 60.94
  • Support Level
  • KZIA $1.31
  • KAVL $1.29
  • Resistance Level
  • KZIA $1.60
  • KAVL $1.42
  • Average True Range (ATR)
  • KZIA 0.26
  • KAVL 0.17
  • MACD
  • KZIA 0.05
  • KAVL 0.00
  • Stochastic Oscillator
  • KZIA 0.64
  • KAVL 78.77

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About KAVL Kaival Brands Innovations Group Inc.

Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.

Share on Social Networks: